Brett P. Monia - Feb 1, 2024 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Signature
By: Patrick R. O'Neil, attorney-in-fact For: Brett P. Monia
Stock symbol
IONS
Transactions as of
Feb 1, 2024
Transactions value $
-$1,160,303
Form type
4
Date filed
2/2/2024, 07:55 PM
Previous filing
Jan 29, 2024
Next filing
Sep 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Award $0 +25.4K +16.71% $0.00 177K Feb 1, 2024 Direct F1
transaction IONS Common Stock Award $0 +20.4K +11.52% $0.00 198K Feb 1, 2024 Direct F2
transaction IONS Common Stock Sale -$1.16M -23.5K -11.89% $49.37 174K Feb 2, 2024 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the second performance period of the grant to the reporting person reported on January 19, 2022. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 150% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal.
F2 Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the final performance period of the grant to the reporting person reported on January 20, 2021. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 100% of target shares and a true-up of 18.63% of target shares pursuant to the alternative calculation. Since this PRSU award paid out less than 100% of target for tranche 1 of such PRSU award, the alternative calculation applies, resulting in an additional payout of 3,206 shares under tranche 1 yielding in the aggregate a total tranche 3 payout of 20,416 shares, or 118.63% of target
F3 The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Performance restricted Stock Unit Agreement and Grant Notice.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.22 to $49.51 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.